# Discover Life Science Canada

# by JETRO Canada and Shonan iPark







# **#2** (#2) Montreal EcoSystem



9am - 10am on 10/1 (Thursday)

8pm-9pm on 9/30(Wednesday)



### Web EX



Meeting number (access code)

131 053 7832

Meeting password

iParkevent123@

https://onetakeda.webex.com/webappng/sites/onetakeda/meeting/download/ 18c028e78af94a0a8df1b12e5a1a4709?siteurl=onetakeda&MTID=m1b041ee0311 43a3995a76b7d008995eb

## **Agenda**

- 1. Opening Remarks
- 2. Overview of Montreal Life Science Ecosystem Montreal International
- 3. Startup Pitch InVivo AI / Jenthera Therapeutics / Optina Diagnostics
- 4. Q&A

- Tyson Garbe, Associate Director, JETRO Toronto
- Yuri Ogiso, Commercial and Business Development, Shonan iPark



# **Overview of Montreal Life Science Ecosystem**



Montreal International

#### **Stéphanie Doyle**

Director, Business Development, Life Sciences & Health Tech Foreign Investments Montreal International



Greater Montreal is one of the east coast's leading life sciences regions. The scientific excellence of Montreal institutions is recognized around the world, and several major investments have recently been made, including the new McGill (MUHC) and Université de Montréal (CHUM and CHU Sainte-Justine) mega hospitals. With access to finance, an entrepreneurial mindset and a recent boom in the sector, Greater Montreal boasts a critical mass of potential strategic partners. Companies that come to Greater Montréal become part of research network that stands at the cutting edge of advances in the industry! The city offers complementary strengths in the fields of biopharmaceuticals, diagnostics, medical devices, health technologies and artificial intelligence. This diverse expertise encourages both business and research collaboration.

https://www.montrealinternational.com/en/

# **Startup Pitch**

INVIVO. AI

InVivo Al











Presenter

#### **Daniel Cohen**

Co-Founder & CEO

InVivo AI is the first company to adapt deep learning to the constraints of drug discovery, with an emphasis on predictive models that can learn from the small, noisy, and imbalanced datasets characteristic of early drug discovery. InVivo works collaboratively with leading pharmaceutical and academic partners to design novel ligands that satisfy multiple pre-specified design criteria, even in the absence of large volumes of training data. The company was launched by top venture capital firms to support commercialization of the founding team's PhD research at the Montreal Institute for Learning Algorithms, and is advised by deep learning pioneer Dr. Yoshua Bengio.

https://www.invivoai.com/

#### Presenter

#### Dr Philip Roche

CEO and interim CSO



Jenthera offers a proprietary precision gene editing platform directly addressing the critical limitations in developing CRISPR therapeutics namely precision, safety, and cost-effectiveness. It allows for the performance of all types of complex gene edits: disruption, insertions and corrections, opening up an unprecedented array of possibilities for the tackling of genetic diseases. Our technology has the potential for developing ground-breaking therapeutics in oncology, cell therapies and broader polygenic gene editing.

Our novel gene editing system achieves unprecedented rates of correction (HDR) and delivers the CRISPR protein with high efficiency and safety. This unlocks access to over 75 000 monogenic plus thousands of complex polygenic diseases, translating CRISPR's potential into powerful medical therapies.

Presenter

#### **David Lapointe**

President & CEO



Optina Diagnostics is a Montreal-based company that focuses on changing mindsets when it comes to brain health by using the retina, the only part of the central nervous system with direct visual access, as a proxy to the brain. Through its Retinal Deep Phenotyping platform, based on its FDA 510(k) cleared hyperspectral retinal camera and image analysis algorithm, which received FDA Breakthrough Device Designation, Optina is offering an accurate, simple, and non-invasive optical test via near-patient eye clinics network. Our aim is to allow early detection of the disease's hallmarks and better understanding of the age-related sources of cognitive decline.

https://www.jenthera.com/

www.optinadx.com